Search

Omeros Corp

Закрыт

СекторЗдравоохранение

18.14 -2.32

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

18.47

Макс.

18.78

Ключевые показатели

By Trading Economics

Доход

-38M

13M

Продажи

19M

29M

P/E

Средняя по отрасли

11.709

57.366

Прибыль на акцию

0.02

Рентабельность продаж

46.381

Сотрудники

175

EBITDA

-40M

18M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+77.32% upside

Дивиденды

By Acuity

Следующий отчет о доходах

12 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

416M

1.4B

Предыдущая цена открытия

20.46

Предыдущая цена закрытия

18.14

Новостные настроения

By Acuity

41%

59%

95 / 340 Рейтинг в Healthcare

Omeros Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

28 авг. 2026 г., 20:07 UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27 авг. 2026 г., 22:01 UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26 авг. 2026 г., 23:06 UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25 авг. 2026 г., 23:12 UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21 авг. 2026 г., 19:16 UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20 авг. 2026 г., 23:32 UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19 авг. 2026 г., 22:51 UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18 авг. 2026 г., 23:16 UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17 авг. 2026 г., 23:06 UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15 авг. 2026 г., 00:01 UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

14 авг. 2026 г., 23:41 UTC

Omeros Corp shares are lower in after-market trading, reflecting broader market sentiment amid a surprise decline in U.S. retail sales for July.

13 авг. 2026 г., 23:06 UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12 авг. 2026 г., 23:51 UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11 авг. 2026 г., 23:41 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10 авг. 2026 г., 23:51 UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8 авг. 2026 г., 00:02 UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7 авг. 2026 г., 23:31 UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6 авг. 2026 г., 23:01 UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5 авг. 2026 г., 23:51 UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4 авг. 2026 г., 23:02 UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3 авг. 2026 г., 23:11 UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1 авг. 2026 г., 00:01 UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31 июл. 2026 г., 23:41 UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30 июл. 2026 г., 16:06 UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29 июл. 2026 г., 18:58 UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28 июл. 2026 г., 19:16 UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

27 июл. 2026 г., 21:01 UTC

Omeros Corp shares are higher in after-market hours, following a broader market trend amid easing geopolitical tensions and declining oil prices.

24 июл. 2026 г., 19:26 UTC

Omeros Corp shares are lower today, continuing a decline since Thursday's close, with no specific news identified to explain the movement.

22 июл. 2026 г., 18:46 UTC

Omeros Corp shares are higher today, continuing an upward trend since Tuesday. Broader market dynamics are influenced by rising crude oil prices amid geopolitical tensions.

21 июл. 2026 г., 23:06 UTC

Omeros Corp. shares traded roughly flat in after-market hours. The stock remains below its 20-day moving average, marking three consecutive lower daily closes.

Сравнение c конкурентами

Изменение цены

Omeros Corp Прогноз

Целевая цена

By TipRanks

77.32% рост

Прогноз на 12 месяцев

Средняя 33 USD  77.32%

Максимум 33 USD

Минимум 33 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Omeros Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

95 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat